Clinical Trials Directory

Trials / Terminated

TerminatedNCT00624546

Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

Effect of Antireflux Therapy on the Expression of Genes Known to be Important in Inflammation, Metaplasia and Neoplasia in Patients With GERD

Status
Terminated
Phase
Study type
Observational
Enrollment
24 (actual)
Sponsor
University of Rochester · Academic / Other
Sex
All
Age
18 Years – 74 Years
Healthy volunteers
Not accepted

Summary

Although the symptomatic and epithelial (histologic and endoscopic) response to antireflux therapy are well known and extensively studied, little is known of the genetic events occurring in response to proton pump inhibitor therapy. Preliminary data from our laboratory has shown, for example, that COX-2 expression is not only elevated in patients with gastroesophageal reflux disease but also can be correlated with pathologic esophageal acid exposure on 24 hour pH monitoring. Similar studies have suggested that antireflux surgery may normalize COX-2 gene expression. In contrast studies following ablation of dysplastic Barrett's epithelium have shown persistence of genetic changes associated with altered cellular function, despite the return of the histologic appearance to normal. Several key mediators of inflammation, metaplasia (Barrett's) and neoplasia have now been well characterized and shown to be important factors in the pathogenesis of esophageal injury. It is likely that successful antireflux therapy returns altered expression of these mediators toward normal although this hypothesis remains largely unexplored. The aim of this study is to investigate gene expression of key mediators of the spectrum of esophageal mucosal injury and the response to antireflux therapy. Hypothesis: Antireflux therapy (proton pump inhibitor and surgical fundoplication) normalizes the expression of genes known to be involved in the pathogenesis of inflammation (esophagitis), metaplasia (Barrett esophagus) and neoplasia (adenocarcinoma).

Detailed description

Aims: To determine the effects of antireflux therapy (pump inhibitor and surgical fundoplication) on gene expression of: 1. inflammation: IL-8, IFN-g, TNF-a. 2. intestinal metaplasia: CDX-1/2, MUC2 and Sonic hedgehog. 3. Neoplasia: Cox-2, VEGF, and EGFR.

Conditions

Interventions

TypeNameDescription
DRUGPrevacid SolutabsBID Prevacid Solutabs
PROCEDUREAntireflux surgeryLap Nissen

Timeline

Start date
2009-01-01
Primary completion
2014-01-01
Completion
2014-01-01
First posted
2008-02-27
Last updated
2015-10-26

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00624546. Inclusion in this directory is not an endorsement.